Used in the management of metastatic paragangliomas and pheochromocytomas, evidence has shown patients with SDHB variants respond remarkably well to temozolomide-based regimens (Hadoux et al., 2014). The gene discussed is SDHB; the disease is hereditary pheochromocytoma-paraganglioma.